Skip to main content

Spero Therapeutics, Inc.

SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001701108

No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Spero Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of SPRO: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders5654−2
Shares14.4M14.2M−176.8K (−1.2%)
Value$20.8M$17.2M−$3.66M (−17.6%)

New holders (5)

Institutions that held Spero Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to SPRO in Q3 2023
InstitutionSharesValue% of portfolio
HRT Financial LP18,627$22.0K0.00%
ERn Financial, LLC15,766$19.1K0.00%
BNP Paribas Arbitrage, SA12$150.00%
Qube Research & Technologies Ltd1$10.00%
Royal Bank of Canada300$00.00%

Sold out (7)

Institutions that held Spero Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of SPRO in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Royce & Associates LP22,851$33.1K
Virtu Financial LLC22,195$32.0K
Citadel Advisors LLC14,956$21.7K
Federated Hermes, Inc.2,647$3.84K
Simplex Trading, LLC2,281$3.00K
Investors Research Corp50$73
FMR LLC4$6